GlassScriptPhysician profile
Cameron S Michael
NPI 1205323433
$7,123.59
in general payments reported to CMS, 2019-2025
30 companies · $2,575 in 2025
The $2,575 reported for 2025 was more than what 77% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $523 · 2023: $1,983 · 2024: $2,043 · 2025: $2,575.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,430 · Travel and Lodging: $171.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,429.51 |
| Travel and Lodging | $170.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,541.14 | 2022-2025 | |
| Pfizer INC. | $1,492.34 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $1,046.70 | 2023-2025 | |
| Abbott Laboratories | $405.73 | 2023 | Infinity, Proclaim |
| Ucb, INC. | $378.06 | 2022-2025 | Rystiggo, Nayzilam, Briviact |
| Amneal Pharmaceuticals LLC | $317.40 | 2022-2025 | Rytary, Crexont, Ongentys |
| Biogen, INC. | $237.61 | 2022-2025 | Vumerity, Tysabri, Skyclarys |
| Sk Life Science, INC. | $197.46 | 2022-2025 | |
| Celgene Corporation | $172.70 | 2023-2025 | Zeposia |
| Biohaven Pharmaceutical Holding Company LTD. | $165.84 | 2022 | |
| Argenx US, INC. | $164.74 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Tg Therapeutics, INC. | $123.33 | 2025 | |
| Acadia Pharmaceuticals INC | $120.87 | 2022-2024 | Nuplazid |
| Eisai INC. | $113.80 | 2023-2025 | |
| Neurocrine Biosciences, INC. | $87.13 | 2022-2024 | Ingrezza, Ongentys |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $83.16 | 2022-2024 | |
| Lundbeck LLC | $79.72 | 2022-2025 | Vyepti |
| Amgen INC. | $77.04 | 2022-2025 | Uplizna |
| Otsuka America Pharmaceutical, INC. | $66.41 | 2023-2025 | Rexulti, Nuedexta |
| Vanda Pharmaceuticals INC. | $51.40 | 2024 | Ponvory |
| Alexion Pharmaceuticals, INC. | $24.32 | 2024 | Ultomiris |
| Teva Pharmaceuticals USA, INC. | $22.79 | 2025 | Austedo Xr |
| Neurelis, INC. | $22.55 | 2025 | Valtoco |
| Axsome Therapeutics, INC. | $22.39 | 2025 | Symbravo |
| Csl Behring | $19.42 | 2025 | Hizentra |
| Harmony Biosciences LLC | $18.72 | 2025 | |
| Catalyst Pharmaceuticals, INC. | $18.44 | 2024 | |
| Genentech USA, INC. | $18.05 | 2025 | Ocrevus Zunovo |
| Nevro Corp. | $17.96 | 2023 | Senza |
| Astrazeneca Pharmaceuticals LP | $16.37 | 2024 | Andexxa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cameron Michael listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.